Recent News

• 04.30.2026 - Larimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich’s Ataxia
• 03.04.2026 - Larimar Therapeutics to Participate in Upcoming Investor Conferences in March
• 02.25.2026 - Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering

Recent Filings

• 04.20.2026 - DEF 14A Other definitive proxy statements
• 04.20.2026 - ARS Annual Report to Security Holders
• 04.10.2026 - PRE 14A Other preliminary proxy statements
• 03.19.2026 - 8-K Current report
• 03.19.2026 - EX-99.1 EX-99.1
• 03.19.2026 - S-8 Securities to be offered to employees in employee benefit plans
• 03.19.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.09.2026 - EX-99.1 EX-99.1
• 03.09.2026 - 8-K Current report
• 03.02.2026 - 4 Statement of changes in beneficial ownership of securities